Product Details

Veratro is a sterile injectable formulation that meets British Pharmacopoeia (BP) standards. Specifically, it delivers Atropine Sulphate IP for use as an anticholinergic agent through the intramuscular (I.M.) or intravenous (I.V.) route. As a result, it offers rapid reversal of bradycardia and muscarinic toxicity across emergency and peri-operative settings.

The injection contains:

• Atropine Sulphate IP (as per specification) – An anticholinergic agent that competitively blocks muscarinic acetylcholine receptors. Consequently, it increases heart rate, reduces secretions, and counteracts the effects of excessive parasympathetic or cholinergic activity.

Physicians use Veratro for the emergency management of symptomatic bradycardia, as a premedication to reduce secretions before anaesthesia, and as an antidote in cases of organophosphate or cholinergic poisoning. In addition, its dual-route (I.M./I.V.) formulation allows flexible administration based on clinical urgency. Because of this profile, Veratro suits hospitals, emergency departments, and operating theatres where rapid anticholinergic intervention is essential.

Key Features:

• Overall, this BP-compliant formulation guarantees pharmaceutical-grade purity
• Additionally, the dual-route (I.M./I.V.) formulation offers flexible clinical use
• Furthermore, each vial delivers precise, validated dosage accuracy
• Notably, rigorous purity and sterility testing backs every stage of manufacturing
• Beyond that, light-protected vial packaging preserves product stability during storage
• Ultimately, a reliable supply chain suits bulk distribution to hospitals, emergency departments, and operating theatres